At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 54 target
Drug / intervention
Cetuximab and irinotecandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05962502Phase 2RecruitingUpdate OverdueUpdated 34mo ago · Completion was 15mo agoEnrollment Stalled
Update Overdue
A Single-arm, Open-label, Phase II Clinical Study of Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
In Brief
A Phase 2 clinical trial evaluating Cetuximab and irinotecan for Metastatic Colorectal Cancer. Currently recruiting, targeting 54 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This is a single-arm, open-label, phase II clinical trial. The goal of this study is to evaluate the efficacy and safety of cetuximab plus irinotecan in patients with NeoRAS wild-type primary left-sided mCRC in third-line therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2024202520262027
First PostedJul 2023
Enrollment StartAug 2023
Primary CompletionMar 2025
TodayJul 2026
Study CompletionDec 2026
First PostedJul 27, 2023
Enrollment StartAug 24, 2023
Primary CompletionMar 30, 2025
Study CompletionDec 30, 2026
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 2.9 years ago
Interventions
Cetuximab and irinotecandrug
chemotherapy plus targeted therapy